Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide ...

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...

Danish company Novo Nordisk has a market cap larger than the entire country's GDP. As it grows, it's having an impact on ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by ...

Novo Nordisk ... before taking these drugs for life. "Because they still have the problem," he said. "The obesity is just a symptom." On a more macro level, Novo Nordisk's runaway success is ...

Novo Nordisk is investing further in obesity and metabolic disease, signing a deal to use Ascendis Pharma’s delivery ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...